A Resource for Healthcare and Social Services Professionals
This event is intended to provide 8 hours of training for prescribers interested in obtaining their buprenorphine waiver.
Communities across the US are affected by the opioid epidemic and every medical specialty cares for patients with opioid use disorders. Of the 2.5 million people in need of treatment, fewer than 1 million receive it. Evidence-based treatments are under-utilized and there is a clear need to increase access to treatment.
In collaboration with the Massachusetts Office Based Addiction Treatment Training and Technical Assistance Program (OBAT TTA) The MGH Substance Use Disorders Initiative is pleased to offer “Buprenorphine Waiver Training” to educate physicians, NPs, PAs and other clinical staff about the fundamentals of addiction medicine as well as buprenorphine, opioid use disorders, and practical patient management.
The Buprenorphine Waiver Training course fulfills 8 hours of the training needed to obtain a waiver to prescribe buprenorphine. The Drug Addiction Treatment Act of 2000 (DATA 2000) requires physicians to complete 8 hours of approved training in order to be eligible for a waiver, and nurse practitioners and physician assistants to complete 24 hours.
* In addition to completing this training, NPs and PAs have other training requirements that must be completed prior to becoming eligible to apply for the waiver. For more information, go to: https://www.samhsa.gov/medication-assisted-treatment/qualify-nps-pas-waivers.
Upon completion of this training, Physician attendees will be able to complete the “Waiver Notification Form” to obtain an “X license” at no cost.
This is an in-person training. There is no option to attend via webinar.
Coffee and breakfast will be served for this event. Attendees are responsible for their own lunch.
If you need assistance on the day of the event, please contact Colleen LaBelle at 617-797-6712.
Upon completion of this activity, participants will be able to:
This activity is intended for prescribers (physicians, nurse practitioners and physician assistants) interested in using medication-assisted treatment protocols for buprenorphine to treat opioid use disorder.
Massachusetts General Hospital Substance Use Disorders Initiative; Boston Medical Center Grayken Center for Addiction, Massachusetts Department of Public Health, Bureau of Substance Addiction Services (DPH/BSAS).
American Academy of Addiction Psychiatry (AAAP) is the DATA 2000 sponsor for this training.
Funding for this initiative was made possible (in part) by grant nos. 5U79TI026556-02 and 3U79TI026556-02S1 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
CME Accreditation: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AAAP and the Boston Medical Center Grayken Center for Addiction, Massachusetts Department of Public Health and the Bureau of Substance Abuse Services (DPH/BSAS). AAAP is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation: American Academy of Addiction Psychiatry designates this live activity for a maximum of 8 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Method of physician participation in the learning process: Credit will only be awarded for completing all of the training. To be awarded a maximum of 8 AMA PRA Category 1 Credits™ and a Buprenorphine Training Completion Certificate you must complete all 8 hours of the course. Those completing the course will be able to complete the waiver application online.